A specialty pharmaceutical company focused on the development and marketing of products in the United States for the treatment of dermatological, aesthetic and podiatric conditions.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Medicis has been given a strong buy recommendation by Standard and Poor's analysts citing their new products for acne treatment and their strong market share in dermal fillers (Restylane and Perlane). From someone in the trenches of treating acne, I have been underwhelmed by the new Ziana and Solodyne products. These don't seem like the right fuel to launch a rocket to soaring profits. The Restylane product will be getting more competition from Juvederm and Radiesse as well as other dermal fillers in the pipeline.